Indoximod

Drug Profile

Indoximod

Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-001; NLG-8189; NSC-721782

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer National Cancer Institute (USA); NewLink Genetics Corporation; University of Minnesota
  • Class Amino acids; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Glioma; Malignant melanoma; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 04 May 2017 NewLink Genetics plans a pivotal trial for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) by the end of 2017
  • 05 Apr 2017 Additional efficacy and safety data from the phase II NLG2103 trial in Melanoma was released by NewLink Genetics
  • 06 Mar 2017 NewLink Genetics has patent protection for Indoximod in USA (NewLink Genetics Form 10-k, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top